2.10
Aytu Biopharma Inc stock is traded at $2.10, with a volume of 27,557.
It is down -0.71% in the last 24 hours and down -7.49% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.115
Open:
$2.15
24h Volume:
27,557
Relative Volume:
0.16
Market Cap:
$21.40M
Revenue:
$66.38M
Net Income/Loss:
$-14.18M
P/E Ratio:
-0.748
EPS:
-2.8074
Net Cash Flow:
$-5.17M
1W Performance:
+5.00%
1M Performance:
-7.49%
6M Performance:
+7.14%
1Y Performance:
+31.25%
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
AYTU
Aytu Biopharma Inc
|
2.10 | 21.55M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
127.69 | 56.36B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.52 | 45.81B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.76 | 43.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
26.32 | 28.67B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
488.43 | 20.92B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong - MSN
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - ACCESS Newswire
Aytu BioPharma (NASDAQ: AYTU) to Showcase at NobleCon21, Dec. 3 Presentation Webcast - Stock Titan
Aytu BioPharma Inc AY20 Stock Analysis and ForecastFundamental Strength Indicators & Superior Trading Strategies - earlytimes.in
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - MSN
Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance
Published on: 2025-11-21 03:45:24 - newser.com
Why Aytu BioPharma Inc. (AY20) stock is trending on social mediaOil Prices & Real-Time Stock Entry Alerts - newser.com
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulusJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Published on: 2025-11-20 04:27:18 - newser.com
Is Aytu BioPharma Inc. stock cheap at current valuationJuly 2025 Selloffs & AI Driven Price Predictions - newser.com
What risks investors should watch in Aytu BioPharma Inc. stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Pre Market Movers: NUTX, AYTU, NOTV Swing Big - RTTNews
What MACD signals say about Aytu BioPharma Inc.July 2025 Update & Low Drawdown Trading Techniques - newser.com
Why Aytu BioPharma Inc. stock remains resilientJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Regression analysis insights on Aytu BioPharma Inc. performance2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Aytu BioPharma : Corporate Presentation November 2025 View Presentation - MarketScreener
How Aytu BioPharma Inc. (AY20) stock moves in volatile trading sessionsDay Trade & Daily Technical Stock Forecast Reports - newser.com
Will Aytu BioPharma Inc. stock attract more institutional investorsWeekly Volume Report & Community Shared Stock Ideas - newser.com
Aytu BioPharma, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
How to escape a deep drawdown in Aytu BioPharma Inc.Market Activity Report & High Accuracy Investment Signals - newser.com
Does Aytu BioPharma Inc. qualify in momentum factor screeningTrade Risk Summary & Consistent Return Strategy Ideas - newser.com
Is Aytu BioPharma Inc. stock ready for a breakoutTake Profit & Low Drawdown Investment Ideas - newser.com
Will Aytu BioPharma Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - newser.com
Relative strength of Aytu BioPharma Inc. in sector analysisWeekly Profit Recap & Verified Momentum Stock Watchlist - newser.com
Understanding Aytu BioPharma Inc.’s price movementJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2026 Earnings Call Transcript - Insider Monkey
Will Aytu BioPharma Inc. (AY20) stock keep high P E multiples2025 Technical Overview & Stock Portfolio Risk Management - newser.com
Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock By Investing.com - Investing.com Australia
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... By GuruFocus - Investing.com Canada
Aytu BioPharma Reports Q1 2026 Earnings and EXXUA Launch Plans - TipRanks
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Inc (AYTU) Q1 2026 Earnings Call Highlights: Strong ADHD Portfolio Performance ... - Yahoo Finance
Transcript : Aytu BioPharma, Inc., Q1 2026 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Aytu BioPharma's Q1 2025 shows stable stock By Investing.com - Investing.com UK
Earnings call transcript: Aytu BioPharma’s Q1 2025 shows stable stock - Investing.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):